within Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01E_ProteinKinaseInhibitors.L01EX17_Capmatinib;

model Capmatinib
  extends Pharmacolibrary.Drugs.ATC.L.L01EX17;

  annotation (Documentation(
info       = "<html><body><table><tr><td>Drug:</td><td>L01EX17</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Capmatinib is a highly selective, potent inhibitor of the MET receptor tyrosine kinase, used primarily for the treatment of non-small cell lung cancer (NSCLC) with mutations leading to MET exon 14 skipping. It is an approved oral targeted therapy for adult patients with metastatic NSCLC harboring MET exon 14 skipping alterations.</p><h4>Pharmacokinetics</h4><p>Mean pharmacokinetic parameters in adult patients with advanced solid tumors including NSCLC after repeated oral dosing; data mainly from phase 1 and phase 2 studies; healthy volunteer data show similar trends.</p><h4>References</h4><ol><li><p>Chen, X, et al., &amp; Marbury, TC (2022). Pharmacokinetics of capmatinib in participants with hepatic impairment: A phase 1, open-label, single-dose, parallel-group study. <i>British journal of clinical pharmacology</i> 88(1) 91–102. DOI:<a href=\"https://doi.org/10.1111/bcp.14929\">10.1111/bcp.14929</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/34046915/\">https://pubmed.ncbi.nlm.nih.gov/34046915</a></p></li><li><p>Chen, X, et al., &amp; Mau-Sorensen, M (2023). Effect of capmatinib on the pharmacokinetics of substrates of CYP3A (midazolam) and CYP1A2 (caffeine) in patients with MET-dysregulated solid tumours. <i>British journal of clinical pharmacology</i> 89(3) 1046–1055. DOI:<a href=\"https://doi.org/10.1111/bcp.15544\">10.1111/bcp.15544</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/36131603/\">https://pubmed.ncbi.nlm.nih.gov/36131603</a></p></li><li><p>Grande, E, et al., &amp; Cui, X (2021). Effect of capmatinib on the pharmacokinetics of digoxin and rosuvastatin administered as a 2-drug cocktail in patients with MET-dysregulated advanced solid tumours: A phase I, multicentre, open-label, single-sequence drug-drug interaction study. <i>British journal of clinical pharmacology</i> 87(7) 2867–2878. DOI:<a href=\"https://doi.org/10.1111/bcp.14697\">10.1111/bcp.14697</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/33300203/\">https://pubmed.ncbi.nlm.nih.gov/33300203</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
end Capmatinib;
